DOCSLIB.ORG

The Ketamine Metabolite 2R,6R-Hydroxynorketamine Blocks NMDA Receptors and Impacts Downstream Signaling Linked to Antidepressant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Ketamine Metabolite 2R,6R-Hydroxynorketamine Blocks NMDA Receptors and Impacts Downstream Signaling Linked to Antidepressant HOT TOPICS ..................................................................................................................................................................... 221 Ingelheim. Dr Cunningham declares no conflict of interest. ACKNOWLEDGMENTS We thank Ms Christina Merritt for the design of the figure. F Gerard Moeller1 and Kathryn A Cunningham2 1Department of Psychiatry, Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, USA; 2Department of Pharmacology and Toxicology, Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, USA E-mail: [email protected] or [email protected] Figure 1. Either a μ-opioid receptor partial agonist, a full 5-HT receptor (5-HT R) agonist, or a .............................................................................................. 2C 2C Cunningham KA, Anastasio NC (2014). Serotonin at combination may afford gains in reducing relapse vulnerability and extending abstinence in opioid use the nexus of impulsivity and cue reactivity in μ disorder (OUD). Partial agonist actions at the -opioid receptor reduce the rewarding effects of cocaine addiction. Neuropharmacology 76 Pt B: opioids and withdrawal. The selective 5-HT2CR full agonist lorcaserin suppresses oxycodone intake 460–478. and associated cue reactivity as well as impulsivity. Low-dose combinations of a μ-opioid receptor Lutfy K, Cowan A (2004). Buprenorphine: a unique partial agonist plus the non-opioid lorcaserin may provide an additional new avenue to support drug with complex pharmacology. Curr Neurophar- recovery in OUD patients. While the brain locus for a potential receptor–receptor interaction is macol 2: 395–402. Neelakantan H, Holliday ED, Fox RG, Stutz SJ, unknown, both the μ-opioid receptor and 5-HT2CR are co-expressed in nodes of the limbic- corticostriatal circuitry engaged in drug reward and relapse vulnerability. The FDA-approved OUD Comer SD, Haney M et al (2017). Lorcaserin suppresses oxycodone self-administration and medication buprenorphine is a μ-opioid receptor partial agonist, but is not selective given its complex δ κ relapse vulnerability in rats. ACS Chem Neurosci 8: actions at -, -, and nociceptin/opioid receptor-like receptors (NOP or ORL-1) (Lutfy and Cowan, 1065–1073. μ 2004). Thus, other -opioid partial agonists may be needed to test the hypothesis that low-dose Shanahan WR, Rose JE, Glicklich A, Stubbe S, combinations with lorcaserin may add value in OUD medication-assisted therapy. Sanchez-Kam M (2016). Lorcaserin for smoking cessation and associated weight gain: a precipitated withdrawal following events, for example. It is also possible randomized 12-week clinical trial. Nicotine Tob Res 2016 Nov 4. ppi: ntw301. (e-pub ahead chronic opioid exposure in mice that low doses of lorcaserin adminis- of print). (Wu et al, 2015). Thus, the non- tered in combination with a partial μ- Volkow ND, Frieden TR, Hyde PS, Cha SS opioid medication lorcaserin acts as a opioid agonist, with limited abuse (2014). Medication-assisted therapies–tackling the opioid-overdose epidemic. NEnglJMed370: 5-HT2CR agonist to influence aspects liability but efficacy to suppress 2063–2066. of opioid-evoked behaviors, suggest- opioid-induced euphoria and withdra- Wu X, Pang G, Zhang YM, Li G, Xu S, Dong L et al ing that the 5-HT Rsystemmay wal may reduce relapse risk via regula- (2015). Activation of serotonin 5-HT(2C) receptor 2C suppresses behavioral sensitization and naloxone- play a key role in the shared mechan- tion of two signaling pathways. The precipitated withdrawal symptoms in heroin- isms for addiction and relapse vul- neurochemical mechanisms and sites treated mice. Neurosci Lett 607:23–28. nerability across psychostimulant of action for 5-HT2CR systems to Neuropsychopharmacology Reviews (2018) 43, 220–221. andopioiddrugclasses. control opioid-related behaviors are doi:10.1038/npp.2017.192 The development of pain medica- also of interest. Finally, preclinical tions with analgesic efficacy, but re- studies to evaluate low-dose combina- μ duced abuse liability, remains a high tions of a partial -opioid agonist plus priority. Of equally high priority is the lorcaserin will provide insight into the The Ketamine identification of therapeutic interven- potential for translational value in Metabolite 2R,6R- tions that increase the maintenance of clinical trials geared to reduce the abstinence after cessation of opioid devastation of opioid overdose Hydroxynorketamine intake, even in high drug cue environ- and OUD. Blocks NMDA Receptors ments. A selective 5-HT2CR agonist, and Impacts such as lorcaserin, may provide a new Downstream Signaling avenue to add value to the outcomes of FUNDING AND DISCLOSURE medication-assisted treatment in OUD Drs Moeller and Cunningham are Linked to Antidepressant (Figure 1). The next step is to expand supported by grants NIDA U54 Effects the present data set to definitively test DA038999 and NIDA P50 DA033935. the hypotheses that lorcaserin inhibits Dr Moeller is an uncompensated con- Clinical studies have demonstrated a opioid withdrawal and countermands sultant for INDIVIOR and receives reproducible rapid antidepressant stress- and/or opioid-triggered relapse research support from Boehringer- effect of low-dose ketamine in patients ................................................................................................................................................... Neuropsychopharmacology HOT TOPICS ..................................................................................................................................................................... 222 with depressive symptoms. However, signaling pathway and effects on role of NMDAR-block-mediated sig- ketamine’s dissociative side effects AMPAR-mediated potentiation—sans naling in triggering the antidepressant and abuse potential has led to the NMDAR block—prompted us to in- effects of ketamine and 2R,6R-HNK. search for identification of alternative vestigate the impact of 2R,6R-HNK on compounds that trigger rapid antide- NMDAR-mediated neurotransmis- FUNDING AND DISCLOSURE pressant effects without the psychoto- sion. In recent experiments, we mimetic side effects. A successful showed that 2R,6R-HNK can swiftly This work was supported by National effort will require elucidation of the inhibit NMDAR transmission up to Institutes of Health Grants MH070727 molecular mechanisms that elicit the 50% at concentrations needed to (LMM) and MH066198 (ETK). LMM antidepressant effects of ketamine. In trigger the intracellular signaling path- is a consultant for Fortress Biotech. 2011, our group proposed a synaptic way involved in the potentiation of ETK declares no conflict of interest. signaling pathway that can account for synaptic AMPAR responses, strongly ketamine’s antidepressant-like effects supporting a role for NMDAR- Ege T Kavalali1 and Lisa M Monteggia1 1 in preclinical animal models (Autry blockade in this effect (Suzuki et al, Department of Neuroscience, the University of Texas Southwestern Medical Center, Dallas, TX, USA et al, 2011). Specifically, we showed 2017). Further characterization E-mail: [email protected] that ketamine-mediated block of showed that the effect of 2R,6R-HNK resting synaptic NMDA receptor on individual NMDA-mEPSCs mi- (NMDAR) activity—driven by sponta- micked those of ketamine, demonstrat- .............................................................................................. — — — Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, neous glutamate release leads to de- ing that 2R,6R HNK like ketamine Cheng P et al (2011). NMDA receptor blockade at activation of eEF2 kinase resulting in selectively inhibits NMDARs while they rest triggers rapid behavioural antidepressant dephosphorylation of its sole known are open (Suzuki et al, 2017). Our study responses. Nature 275:91–95. μ Maeng S, Zarate CA Jr, Du J, Schloesser RJ, target eEF2. The dephosphorylation of demonstrated that 50 M 2R,6R-HNK McCammon J, Chen G et al (2008). Cellular eEF2 results in desuppresion of den- blocks synaptic NMDARs and thus mechanisms underlying the antidepressant effects dritic protein translation and a rapid 2R,6R-HNK is not ‘NMDAR-indepen- of ketamine: role of alpha-amino-3-hydroxy-5- ’ methylisoxazole-4-propionic acid receptors. Biol subsequent increase in brain-derived dent in its action. Although we used a Psychiatry 63: 349–352. neurotrophic factor (BDNF) expres- higher concentration than the 10 μM Nosyreva E, Szabla K, Autry AE, Ryazanov AG, sion. Released BDNF activates TrkB 2R,6R-HNK—suggested as the brain Monteggia LM, Kavalali ET (2013). Acute suppres- sion of spontaneous neurotransmission drives receptors and triggers a subsequent concentration in rodents following a synaptic potentiation. J Neurosci 33: 6990–7002. potentiation of AMPA receptor (AM- behaviorally effective antidepressant Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, PAR)-mediated synaptic transmission dose of 10 mg/kg 2R,6R-HNK (Zanos Monteggia LM (2017). The ketamine metabolite — hydroxynorketamine impacts downstream signal- in the hippocampus, providing a et al, 2016) a recent study was not ing via NMDA receptor inhibition. Nature 546: synaptic basis for the antidepressant able to detect antidepressant effects of E1–E3. effects of ketamine (Autry et al,2011; 10 mg/kg 2R,6R-HNK in the same Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K (2017). (R)-Ketamine shows greater potency and Nosyreva et al, 2013). Consistent with behavioral
Load more

Recommended publications
  • Pharmacogenetics of Ketamine Metabolism And
    Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine Yibai Li B.HSc. (Hons) Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, The University of Adelaide September 2014 A thesis submitted for the Degree of PhD (Medicine) Table of contents TABLE OF CONTENTS .............................................................................................. I LIST OF FIGURES ....................................................................................................IV LIST OF TABLES ......................................................................................................IV ABSTRACT ............................................................................................................... V DECLARATION .......................................................................................................VIII ACKNOWLEDGEMENTS ..........................................................................................IX ABBREVIATIONS .....................................................................................................XI CHAPTER 1. INTRODUCTION .................................................................................. 1 1.1 A historical overview of ketamine ........................................................................................ 1 1.2 Structure and Chemistry ....................................................................................................... 3 1.3 Classical analgesic mechanisms of ketamine ...................................................................
    [Show full text]
  • Opioid Withdrawal ��������������������������������������������������������������������������������������������������� 15 Mark S
    Magdalena Anitescu Honorio T. Benzon Mark S. Wallace Editors Challenging Cases and Complication Management in Pain Medicine 123 Challenging Cases and Complication Management in Pain Medicine Magdalena Anitescu Honorio T. Benzon • Mark S. Wallace Editors Challenging Cases and Complication Management in Pain Medicine Editors Magdalena Anitescu Honorio T. Benzon Department of Anesthesia and Critical Care Department of Anesthesiology University of Chicago Medicine Northwestern University Chicago, IL Feinberg School of Medicine USA Chicago, IL USA Mark S. Wallace Division of Pain Medicine Department of Anesthesiology University of California San Diego School of Medicine La Jolla, CL USA ISBN 978-3-319-60070-3 ISBN 978-3-319-60072-7 (eBook) https://doi.org/10.1007/978-3-319-60072-7 Library of Congress Control Number: 2017960332 © Springer International Publishing AG 2018 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Fundamentals of C.R.P.S
    FUNDAMENTALS OF C.R.P.S. PHILIP GETSON, D.O. SEPTEMBER 11, 2015 R.S.D. Association National Conference I DON’T KNOW ! Philip Getson, D.O. October 22, 1999 Third National RSD Association Conference Atlantic City N.J. HISTORY The first mention of CRPS dates back to the 17th Century when surgeon Ambrose Pare reported that King Charles IX suffered from persistent pain and contracture of his arm following a bloodletting procedure During the Civil War Mitchell described soldiers suffering from burning pain due to gunshot wounds. He termed this Causalgia In 1900 Sudek described complications of trauma to the limbs with swelling, limitation of motor function and resistance to treatment The term Reflex Sympathetic Dystrophy was first used by Evans in 1946 NOMENCLATURE Causalgia Sudek’s Atrophy Post traumatic Pain Syndrome Post traumatic Painful Arthrosis Sudek’s Dystrophy Post Traumatic Edema Reflex Dystrophy Shoulder Hand Syndrome Chronic Traumatic Edema Algodystrophy Peripheral Trophoneurosis Sympathalgia Reflex Sympathetic Dystrophy Reflex Neurovascular dystrophy DEFINITION Complex Regional Pain is a neuropathic/inflammatory pain disorder characterized by: 1. Severe pain that extends beyond the injured area and is disproportionate to the inciting event. 2. Autonomic dysregulation 3. Edema – usually neuropathic in nature 4. Movement disorders 5. Atrophy and/or dystrophy CAUSE There is no single cause of CRPS Some more common are: sprain, contusion, surgery, fracture, infections, myocardial infarctions, carpel tunnel syndrome,
    [Show full text]
  • Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events Christine Marie Emnett Washington University in St
    Washington University in St. Louis Washington University Open Scholarship Arts & Sciences Electronic Theses and Dissertations Arts & Sciences Winter 12-15-2014 Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events Christine Marie Emnett Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds Part of the Biology Commons Recommended Citation Emnett, Christine Marie, "Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events" (2014). Arts & Sciences Electronic Theses and Dissertations. 347. https://openscholarship.wustl.edu/art_sci_etds/347 This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Neurosciences Dissertation Examination Committee: Steven Mennerick, Chair James Huettner Daniel Kerschensteiner Peter D. Lukasiewicz Joseph Henry Steinbach Modulation of NMDA Receptor Activity During Physiological and Pathophysiological Events by Christine Marie Emnett A dissertation presented to the Graduate School of Arts and Sciences of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy December 2014
    [Show full text]
  • Neurotransmission Product Guide | Edition 1
    Neurotransmission Product Guide | Edition 1 Delphinium Delphinium A source of Methyllycaconitine Contents by Research Area: • Dopaminergic Transmission • Glutamatergic Transmission • Opioid Peptide Transmission • Serotonergic Transmission • Chemogenetics Tocris Product Guide Series Neurotransmission Research Contents Page Principles of Neurotransmission 3 Dopaminergic Transmission 5 Glutamatergic Transmission 6 Opioid Peptide Transmission 8 Serotonergic Transmission 10 Chemogenetics in Neurotransmission Research 12 Depression 14 Addiction 18 Epilepsy 20 List of Acronyms 22 Neurotransmission Research Products 23 Featured Publications and Further Reading 34 Introduction Neurotransmission, or synaptic transmission, refers to the passage of signals from one neuron to another, allowing the spread of information via the propagation of action potentials. This process is the basis of communication between neurons within, and between, the peripheral and central nervous systems, and is vital for memory and cognition, muscle contraction and co-ordination of organ function. The following guide outlines the principles of dopaminergic, opioid, glutamatergic and serotonergic transmission, as well as providing a brief outline of how neurotransmission can be investigated in a range of neurological disorders. Included in this guide are key products for the study of neurotransmission, targeting different neurotransmitter systems. The use of small molecules to interrogate neuronal circuits has led to a better understanding of the under- lying mechanisms of disease states associated with neurotransmission, and has highlighted new avenues for treat- ment. Tocris provides an innovative range of high performance life science reagents for use in neurotransmission research, equipping researchers with the latest tools to investigate neuronal network signaling in health and disease. A selection of relevant products can be found on pages 23-33.
    [Show full text]
  • FSU ETD Template
    Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2018 Sex Differences in the Effects of Low- Dose Ketamine in Rats: A Behavioral, Pharmacokinetic and Pharmacodynamic Analysis Samantha K. Saland Follow this and additional works at the DigiNole: FSU's Digital Repository. For more information, please contact [email protected] FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE SEX DIFFERENCES IN THE EFFECTS OF LOW-DOSE KETAMINE IN RATS: A BEHAVIORAL, PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS By SAMANTHA K. SALAND A Dissertation submitted to the Department of Biomedical Sciences in partial fulfillment of the requirements for the degree of Doctor of Philosophy 2018 Samantha Saland defended this dissertation on April 18, 2018. The members of the supervisory committee were: Mohamed Kabbaj Professor Directing Dissertation Thomas Keller University Representative James Olcese Committee Member Branko Stefanovic Committee Member Zuoxin Wang Committee Member The Graduate School has verified and approved the above-named committee members, and certifies that the dissertation has been approved in accordance with university requirements. ii I dedicate this work to my loving husband and to my parents—without their endless encouragement and unconditional support throughout the years, this would not have been possible. iii ACKNOWLEDGEMENTS I would like to acknowledge all those in the Department of Biomedical Sciences here at Florida State University who have made it possible for me to succeed, not only through financial and research support, but by providing an environment of opportunity, understanding and encouragement time and again during my time in the graduate program. I would also like to express my gratitude to my committee members for their continued guidance and support throughout all these years—thank you for challenging me and expanding my continuous search for knowledge.
    [Show full text]
  • WO 2013/056229 Al 18 April 2013 (18.04.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/056229 Al 18 April 2013 (18.04.2013) P O P C T (51) International Patent Classification: Marc C. [US/US]; 1120 Deer Run Court, Southampton, C07C 225/20 (2006.01) A61P 25/28 (2006.01) Pennsylvania 18966 (US). GOLDBERG, Michael E. C07C 237/02 (2006.01) A61P 25/00 (2006.01) [US/US]; 113 North Bread Street, Unit 9E, Philadelphia, C07D 295/155 (2006.01) A61K 31/133 (2006.01) Pennsylvania 19106 (US). C07D 295/145 (2006.01) A61K 31/122 (2006.01) (74) Agent: MAXWELL, Leslie-Anne; Cantor Colburn LLP, A61P 25/04 (2006.01) 20 Church Street, 22nd Floor, Hartford, Connecticut 06103 (21) International Application Number: (US). PCT/US2012/060256 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 October 2012 (15.10.2012) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, English (25) Filing Language: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/547,336 14 October 201 1 (14. 10.201 1) US NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (71) Applicants: THE UNITED STATES OF AMERICA, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, AS REPRESENTED BY THE SECRETARY, DE¬ TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, PARTMENT OF HEALTH AND HUMAN SERVICES ZM, ZW.
    [Show full text]
  • (R,S)-Ketamine, (2R,6R)-Hydroxynorketamine, and (2S,6S)-Hydroxynorketamine
    www.nature.com/npp ARTICLE Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine Briana K. Chen 1, Victor M. Luna2,3, Christina T. LaGamma2,9, Xiaoming Xu4,5, Shi-Xian Deng4,5, Raymond F. Suckow3,6, Thomas B. Cooper3,6, Abhishek Shah 7, Rebecca A. Brachman3, Indira Mendez-David8, Denis J. David8, Alain M. Gardier8, Donald W. Landry4,5 and Christine A. Denny 2,3 Enhancing stress resilience in at-risk populations could significantly reduce the incidence of stress-related psychiatric disorders. We have previously reported that the administration of (R,S)-ketamine prevents stress-induced depressive-like behavior in male mice, perhaps by altering α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated transmission in hippocampal CA3. However, it is still unknown whether metabolites of (R,S)-ketamine can be prophylactic in both sexes. We administered (R,S)-ketamine or its metabolites (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) and (2S,6S)-hydroxynorketamine ((2S,6S)- HNK) at various doses 1 week before one of a number of stressors in male and female 129S6/SvEv mice. Patch clamp electrophysiology was used to determine the effect of prophylactic drug administration on glutamatergic activity in CA3. To examine the interaction between ovarian hormones and stress resilience, female mice also underwent ovariectomy (OVX) surgery and a hormone replacement protocol prior to drug administration. (2S,6S)-HNK and (2R,6R)-HNK protected against distinct stress- 1234567890();,: induced behaviors in both sexes, with (2S,6S)-HNK attenuating learned fear in male mice, and (2R,6R)-HNK preventing stress- induced depressive-like behavior in both sexes.
    [Show full text]
  • Efficacy and Safety of Intranasal Esketamine When Tapered from Twice-Weekly Dosing to Once Per Week Dosing and Then Dosing Once Every Other Week
    Janssen Research & Development * Clinical Protocol A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE) Protocol ESKETINTRD2003; Phase 2a AMENDMENT INT-3 JNJ-54135419 (esketamine) *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Infectious Diseases BVBA; Janssen R&D Ireland; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol. This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312). EudraCT NUMBER: 2013-004005-11 Status: Approved Date: 28 April 2014 Prepared by: Janssen Research & Development, LLC EDMS No & Version: EDMS-ERI-71950055:5.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or confidential.
    [Show full text]
  • (2R,6R)-Hydroxynorketamine (HNK) Targets Glucocorticoid
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.03.280834; this version posted March 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title Rapid acting antidepressant (2R,6R)-hydroxynorketamine (HNK) targets glucocorticoid receptor signaling: a longitudinal cerebrospinal fluid proteome study Authors David P. Herzog1,* MD; Natarajan Perumal2,* PhD; Caroline Manicam2 PhD; Giulia Treccani1,3,4 PhD; Jens Nadig1; Milena Rossmanith2; Jan Engelmann1 MD; Tanja Jene1 MS; Annika Hasch1 MS; Michael A. van der Kooij1,5 PhD; Klaus Lieb1,5 MD; Nils C. Gassen6 PhD; Franz H. Grus2 MD PhD; Marianne B. Müller1,5 MD Affiliations 1Department of Psychiatry and Psychotherapy and Focus Program Translational Neurosciences, Johannes Gutenberg University Medical Center Mainz, Mainz, Germany. 2Experimental and Translational Ophthalmology, Department of Ophthalmology, Johannes Gutenberg University Medical Center, Mainz, Germany. 3Institute for Microscopic Anatomy and Neurobiology, Johannes Gutenberg University Medical Center, Mainz, Germany. 4Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark. 5Leibniz Institute for Resilience Research, Mainz, Germany. 6Neurohomeostasis Research Group, Department of Psychiatry and Psychotherapy, University Medical Center Bonn, Bonn, Germany. *Shared first authorship in alphabetical order. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.03.280834;
    [Show full text]
  • ACNP 57Th Annual Meeting: Poster Session I
    www.nature.com/npp ABSTRACTS COLLECTION ACNP 57th Annual Meeting: Poster Session I Sponsorship Statement: Publication of this supplement is sponsored by the ACNP. Individual contributor disclosures may be found within the abstracts. Asterisks in the author lists indicate presenter of the abstract at the annual meeting. https://doi.org/10.1038/s41386-018-0266-7 M1. Lifespan Effects of Early Life Stress on Aging-Related Conclusions: These findings suggest a role for ELA in the form Trajectory of Memory Decline of poor maternal care in increasing the likelihood to development of peripheral IR, altered central glucocorticoid function and Benedetta Bigio*, Danielle Zelli, Timothy Lau, Paolo de Angelis, corresponding anxiety states in adulthood, and that these factors Daniella Miller, Jonathan Lai, Anisha Kalidindi, Susan Harvey, Anjali may encode lifelong susceptibility to pathophysiological aging. Ferris, Aleksander Mathe, Francis Lee, Natalie Rasgon, Bruce McEwen, Given our earlier reported association between IR and a LAC Carla Nasca deficiency, a candidate biomarker of major depression that is a risk factor for aging-associated memory decline, we are currently Rockefeller University, New York, New York, United States assessing LAC levels in this mechanistic framework. This model may provide endpoints for identification of early windows of opportunities for preemptive tailored interventions. Background: Early life adversities (ELA), such as variations in Keywords: Early Life Adversity, Glucocorticoids, Insulin Resis- maternal care of offspring, are critical factors underlying the tance, Glutamate, Memory Function individual likelihood to development of multiple psychiatric and Disclosure: Nothing to disclose. medical disorders. For example, our new translation findings suggest a role of ELA in the form of childhood trauma on fi development of metabolic dysfunction, such as a de ciency in M2.
    [Show full text]